No Data
No Data
Adaptimmune Therapeutics: Balancing Positive Momentum With Strategic Pauses – A Hold Rating Analysis
Barclays Remains a Sell on Adaptimmune Therapeutics (ADAP)
Express News | Adaptimmune Therapeutics PLC : Guggenheim Cuts Target Price to $1.75 From $3
Scotiabank Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $1.4
Adaptimmune Therapeutics | 10-K: FY2024 Annual Report
Express News | Adaptimmune Therapeutics PLC - Enters Amendment to Loan and Security Agreement - SEC Filing